World
Vertex kidney disease drug, Summit, Capricor: Readout Newsletter Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk.
Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk.
Dr. Kai NakamuraChief Science CorrespondentPublished Oct 29, 2026 at 9:48 PM EDT · 1 min read
Vertex kidney disease drug, Summit, Capricor: Readout Newsletter Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk. Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk.
Continue reading
Latest →Corrections, sourcing and article labels are part of the publication record. See our editorial standards.